
About Immatics
Immatics is a publicly listed company based in Tubingen (Germany) founded in 2000. T-cell-based immunotherapies for cancer treatment are developed. Immatics has raised $236.4 million across 9 funding rounds from investors including 3i Group, European Union and KfW. The company has 423 employees. Its website immatics.com draws about 17 thousand monthly visits. Immatics offers products and services including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT. Its focus areas include Life Sciences, Cell Therapy, Adoptive Cell Therapy and T-Cell. Its legal entity is Immatics N.V.
Company details
Founded in 2000 and based in Tubingen, Germany, the company operates in the biotechnology sector, focusing on cancer immunotherapies. A proprietary platform called XPRESIDENT is utilized to identify and validate cancer-specific antigens. Adoptive cell therapies and bispecific T-cell receptors are subsequently developed for cancer treatment. The IMA101 product is generated through the ACTolog approach, employing T-cells from peripheral blood with targeted selectivity.
- Headquarters Tubingen, Germany
- Employees 423
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website immatics.com
- Social LinkedIn X Instagram
- Legal Name Immatics N.V.
- Annual Revenue$54.47 M (USD)-67.68as on Dec 31, 2025
- Net Profit-$221.71 M (USD)-1446.84as on Dec 31, 2025
- EBITDA-$196.77 M (USD)-587.27as on Dec 31, 2025
- Total Equity Funding$236.4M (USD)
in 9 rounds
- Latest Funding Round$35M (USD), Post-IPO
Jul 2023
- Investors3i Group
& 15 more
- Employee Count423
Products & Services of Immatics
Immatics offers a comprehensive portfolio of products and services, including Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT.
T cell-based treatments targeting solid tumors in clinical trials.
Bispecific antibodies for enhancing T cell responses against cancer.
Innovative cell therapies for improved cancer treatment efficacy.
Funding Insights of Immatics
Immatics has successfully raised a total of $236.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $35 million completed in July 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $236.4M
- Total Rounds 9
- Last Round Post-IPO β $35M
- First Round $10.09M
(Mar 2004)
- Investors Count 16
All 9 funding rounds of Immatics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2023 | $35M | Post-IPO | β | β | |
| Aug 2020 | Post-IPO | β | β | ||
| Oct 2017 | $58M | Series E | β | Dievini, Amgen Business Development | |
| Jan 2016 | $1.41M | Grant | β | β | |
| Oct 2013 | $46M | Series D | β | Wellington Partners Venture Capital, Dievini | β |
| Jun 2013 | Series C | β | b2venture | β | |
| Sep 2010 | $70.35M | Series C | β | MIG Fonds | |
| Feb 2007 | $51.96M | Series B | β | 3i Group, Wellington Partners Venture Capital | |
| Mar 2004 | $10.09M | Series A | β | Wellington Partners Venture Capital, 3i Group |
16 investors in total: 16 institutional.
Investors in Immatics
Immatics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include 3i Group, European Union and KfW.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and private equity investments are managed. | asiaalpha.com | New York, United States | ||
Investments are made in early-stage healthcare startups. | wellington-partners.com | Munich, Germany | ||
Investments are made in life and health sciences companies. | dievini.de | Germany | ||
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Venture capital is provided to innovative startups by b2venture. | b2venture.vc | St. Gallen, Switzerland | ||
Venture capital investments in technology companies are managed by MIG Fonds. | mig-fonds.de | Germany | ||
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
NTEC Kuwait is engaged in technology and knowledge transfer services. | ntec.com.kw | Kuwait City, Kuwait | ||
Merifin Capital is recognized as a European private investment group. | merifin.com | Brussels, Belgium |
Investor details for Immatics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Immatics
134 people are tracked at Immatics (56 in leadership, 13 in board & advisors, 65 in team); the tracked headcount is 423.
| Name | Role | Group |
|---|---|---|
Carsten Reinhardt | Managing Director & CDO | Leadership |
Ephraim Hofsäß | Vice President SEC Reporting & Accounting | Leadership |
Amie Krause | Chief People Officer | Leadership |
Cindy Greysen | Executive Director, Medical Affairs | Leadership |
Silvia Kestler | Associate Director Clinical Operations | Leadership |
Venkat Ramanan | Chief Financial Officer | Leadership |
Tanja Kieschoweit | Director Clinical Operations | Team Lead Site Operations | Leadership |
Michael Mølhøj | VP, CMC | Leadership |
Rainer Kramer | Managing Director & Chief Business Officer | Leadership |
Cedrik Britten | Chief Medical Officer | Leadership |
Toni Weinschenk | Chief Innovation Officer | Leadership |
Harpreet Singh | CEO | Leadership |
Dominik Maurer | VP, Immunology & Site Head Tuebingen | Leadership |
Andrea Mayer | Vice President, Global Head of Clinical Sciences | Leadership |
Nina Stahl | Associate Director, Global Patient Supply | Leadership |
Khalel Iman | Associate Director, Clinical Development | Leadership |
Bettina Brackertz | Associate Director Clinical Safety | Leadership |
Claudia Blattner | Vice President Business Development | Leadership |
Ali Mohamed | VP, CMC | Leadership |
Paula Franson | VP, Medical Affairs | Leadership |
114 more people are available in the full profile.
Complete people profiles for Immatics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Immatics
Immatics is a publicly listed company on the NASDAQ with ticker symbol IMTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Jul 2020
- Listed onNASDAQ: IMTX
- Listed entityImmatics N.V.
- Exchange sectorHealth technology
- ISINNL0015285941
- Share price$6.83 (-5.27% on the day) · 2026-10-13
- Market capitalisation$1.02B
- EPS (diluted, trailing year)$-1.85
- Volume (last session)928,583
Financials of Immatics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $54.5M | -$221.7M | -$196.8M |
| 2024 | $168.6M | $16.5M | -$28.6M |
| 2023 | $58.4M | -$102.3M | -$103.4M |
| 2022 | $181.6M | $39.4M | $38.8M |
| 2021 | $41.1M | -$110.3M | -$96.2M |
Detailed financial statements for Immatics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Immatics
4 dated milestones of Immatics across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Immatics is founded.
- Funding First funding round of $10.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $35.0M.
Web traffic of Immatics
The website of Immatics (immatics.com) receives about 17.1K visits a month and ranks #1,492,078 among all websites worldwide, #1,962 in Biotechnology and Pharmaceuticals.
- Monthly visits17.1K
▼ 8.1% vs previous month
- Unique visitors7.3K
per month
- Global rank#1,492,078
among all websites
- Category rank#1,962
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit1.7
- Average visit25 sec
- DevicesDesktop 33% Β· Mobile 68%
Websites whose visitors overlap most with Immatics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bioregio-stern.de | 100% | 6.8K | #2,397,204 | View details | |
transkript.de | transkript.de | 98% | #2,698,949 | β | |
| ovesco.com | 74% | 6K | #3,167,330 | View details | |
| fiercebiotech.com | 66% | 858.3K | #81,022 | View details | |
| cegat.com | 62% | 30.6K | #1,030,162 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Immatics
Complete news archive for Immatics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immatics
Immatics was founded in 2000 and raised its 1st funding round 4 years after it was founded.
Immatics is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
Immatics is a funded company, having raised a total of $236.4M across 9 funding rounds to date. The company's 1st funding round was a Series A of $10.09M, raised on Mar 2004.
Immatics has 423 employees.
Annual revenue of Immatics is $54.47M as on Dec 31, 2025.
Founded in 2000 and based in Tubingen, Germany, the company operates in the biotechnology sector, focusing on cancer immunotherapies. A proprietary platform called XPRESIDENT is utilized to identify and validate cancer-specific antigens. Adoptive cell therapies and bispecific T-cell receptors are subsequently developed for cancer treatment. The IMA101 product is generated through the ACTolog approach, employing T-cells from peripheral blood with targeted selectivity.
Immatics offers Adoptive Cell Therapies, TCR Bispecifics, and Next-generation ACT.
Yes, Immatics is publicly traded on NASDAQ under the ticker symbol IMTX.
Immatics has 16 investors. Key investors include 3i Group, European Union, KfW, Bristol-Myers Squibb, and DH Capital.
Immatics operates through Immatics N.V..
